PRAC November 2021: updates on COVID-19 vaccines and conclusion of safety signal for Imbruvica
November 10, 2021
During its November 2021 meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has made un update on COVID-19 vaccines and concluded a safety signal for Imbruvica.
Source: FAMHP
PRAC assessing further data on risk of myocarditis and pericarditis with mRNA vaccines
EMA’s safety committee (PRAC) is assessing further data providing more information on the risk of myocarditis and pericarditis following vaccination with COVID-19 vaccines Comirnaty and Spikevax (previously COVID-19 Vaccine Moderna).
COVID-19 vaccines: PRAC finds insufficient evidence on a possible link with multisystem inflammatory syndrome
The PRAC has concluded that there is currently insufficient evidence on a possible link between COVID-19 vaccines and very rare cases of multisystem inflammatory syndrome (MIS).